TEMIXYS is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Celltrion Usa, Inc.. The primary component is Lamivudine; Tenofovir Disoproxil Fumarate.
| Product ID | 72606-002_0732cedf-911f-4b66-b610-3790d1df6b9e |
| NDC | 72606-002 |
| Product Type | Human Prescription Drug |
| Proprietary Name | TEMIXYS |
| Generic Name | Lamivudine And Tenofovir Disoproxil Fumarate |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2018-11-16 |
| Marketing Category | NDA / NDA |
| Application Number | NDA211284 |
| Labeler Name | CELLTRION USA, INC. |
| Substance Name | LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE |
| Active Ingredient Strength | 300 mg/1; mg/1 |
| Pharm Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleosides [CS],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2019-11-07 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA211284 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2019-11-07 |
| Ingredient | Strength |
|---|---|
| LAMIVUDINE | 300 mg/1 |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 32228-004 | TEMIXYS | lamivudine and tenofovir disoproxil fumarate |
| 72606-002 | TEMIXYS | lamivudine and tenofovir disoproxil fumarate |
| 49502-450 | CIMDUO | Lamivudine and Tenofovir Disoproxil Fumarate |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() TEMIXYS 79229584 5652077 Live/Registered |
CELLTRION, INC. 2018-02-01 |